Theravance Biopharma Inc. (TBPH)

26.29
0.81 3.18
NASDAQ : Health Technology
Prev Close 25.48
Open 25.41
Day Low/High 25.32 / 26.42
52 Wk Low/High 21.27 / 40.11
Volume 268.21K
Avg Volume 211.20K
Exchange NASDAQ
Shares Outstanding 54.85M
Market Cap 1.42B
EPS -5.50
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Theravance Biopharma To Host Key Opinion Leader Event Focused On The Unmet Medical Need In The Treatment Of Neurogenic Orthostatic Hypotension

Live Event and Webcast from 12:00 - 1.30 p.m. ET on Thursday, May 24th

Theravance Biopharma Reports Positive New Data From Multiple Studies Of VIBATIV® (telavancin) At 2018 ECCMID™ Conference

Data from TOUR™ Observational Patient Registry Demonstrate Clinical Response Rates with VIBATIV® (telavancin) Treatment Range from 76.5 - 78.8% for Obese and Elderly Patient Subgroups

Antimicrobials Working Group Highlights Member Company Participation At The 28th European Congress Of Clinical Microbiology And Infectious Diseases (ECCMID)

71 Abstracts to be Presented by Coalition Members During the Annual Meeting

Theravance Biopharma Highlights Landmark IMPACT Study Published In NEJM Showing Significant Benefits Of Trelegy Ellipta For COPD Patients

Once-daily Single Inhaler Triple Therapy Superior to Relvar/Breo Ellipta and Anoro Ellipta Across Multiple Endpoints Including Exacerbations, Lung Function and Quality of Life

Noteworthy Wednesday Option Activity: TBPH, MODN, YUM

Noteworthy Wednesday Option Activity: TBPH, MODN, YUM

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Theravance Biopharma, Inc. , where a total of 1,359 contracts have traded so far, representing approximately 135,900 underlying shares.

Theravance Biopharma Enters Global Collaboration With Janssen For TD-1473 In Inflammatory Intestinal Diseases

Theravance Biopharma Enters Global Collaboration With Janssen For TD-1473 In Inflammatory Intestinal Diseases

Theravance Biopharma Together with Janssen will Jointly Develop and Commercialize TD-1473, a Novel, Potent, Orally Administered and Intestinally Restricted pan-Janus Kinase (JAK) Inhibitor

Drug Companies Respond to States Generic Drug Lawsuit

Drug Companies Respond to States Generic Drug Lawsuit

State attorneys general led by Connecticut's George Jepsen said Tuesday that were planning to include Mylan president Rajiv Malik and Emcure Pharmaceuticals Ltd. executive Satish Mehta in an expanded complaint in the federal generic drug antitrust lawsuit.

Biotech Movers: Sarepta, Inovio, Mylan

Biotech Movers: Sarepta, Inovio, Mylan

Sarepta Therapeutics, Inovio Pharmaceuticals and Mylan were among the biotech movers in premarket trading on July 20.

Why Gilead Sciences Is Nearing Yet Another Mind-Bending Breakout

Why Gilead Sciences Is Nearing Yet Another Mind-Bending Breakout

The stock has been on fire.

TBPH Crosses Above Average Analyst Target

In recent trading, shares of Theravance Biopharma, Inc. have crossed above the average analyst 12-month target price of $40.67, changing hands for $40.72/share.

Theravance Biopharma Reaches Analyst Target Price

In recent trading, shares of Theravance Biopharma, Inc. have crossed above the average analyst 12-month target price of $36.50, changing hands for $36.83/share.

Theravance Biopharma Stock Sees Short Interest Increase 12.6%

The most recent short interest data has been released for the 04/28/2017 settlement date, which shows a 683,471 share increase in total short interest for Theravance Biopharma, Inc. , to 6,119,351, an increase of 12.57% since 04/13/2017.

Theravance Biopharma Reaches Analyst Target Price

In recent trading, shares of Theravance Biopharma, Inc. have crossed above the average analyst 12-month target price of $32.00, changing hands for $32.02/share.

Theravance Biopharma Reaches Analyst Target Price

Theravance Biopharma Reaches Analyst Target Price

In recent trading, shares of Theravance Biopharma, Inc. have crossed above the average analyst 12-month target price of $30.40, changing hands for $30.84/share.

Short Interest In Theravance Biopharma Increases 60.2%

Short Interest In Theravance Biopharma Increases 60.2%

The most recent short interest data has been released for the 11/15/2016 settlement date, which shows a 2,092,829 share increase in total short interest for Theravance Biopharma, Inc. , to 5,567,695, an increase of 60.23% since 10/31/2016.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: HSC, MTLS, PBH, SMCI Downgrades: BURL, CWCO, ELTK, IXYS, PEB, POST, RTIX, TBPH, TISA, TTNP, WMT Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

TBPH Crosses Above Average Analyst Target

TBPH Crosses Above Average Analyst Target

In recent trading, shares of Theravance Biopharma, Inc. have crossed above the average analyst 12-month target price of $30.80, changing hands for $31.25/share.

TBPH Crosses Above Average Analyst Target

TBPH Crosses Above Average Analyst Target

In recent trading, shares of Theravance Biopharma, Inc. have crossed above the average analyst 12-month target price of $25.25, changing hands for $25.51/share.

Short Interest In Theravance Biopharma Decreases By 11.6%

Short Interest In Theravance Biopharma Decreases By 11.6%

The most recent short interest data has been released for the 04/15/2016 settlement date, which shows a 423,748 share decrease in total short interest for Theravance Biopharma, Inc. , to 3,245,119, a decrease of 11.55% since 03/31/2016.

Commit To Purchase Theravance Biopharma At $17.50, Earn 13% Annualized Using Options

Commit To Purchase Theravance Biopharma At $17.50, Earn 13% Annualized Using Options

Investors eyeing a purchase of Theravance Biopharma, Inc. shares, but tentative about paying the going market price of $22.06/share, might benefit from considering selling puts among the alternative strategies at their disposal.

TheStreet Quant Rating: D (Sell)